The pharmacological effects of Artabotrys thomsonii, a vine traditionally used against diabetes mellitus, were evaluated in an insulin-resistant diabetes model. Diabetes and hypertension were induced in rats by daily oral administration of 10% fructose (by gavage) and 10% sucrose (in drinking water) for 21 days, followed by intraperitoneal (i.p.) injection of streptozotocin (STZ) (40 mg/kg) on day 22. 100, 200, and 400 mg/kg of the extract were then administered to the diabetic rats from day 49 to day 77. The insulin sensitivity test was also performed on day 29 and day 77. Blood glucose levels were measured every 7 days, while blood pressure was measured on day 49 and day 74. Serum and tissue biochemical parameters were determined at the end of the last treatment. Diabetic rats exhibited hyperglycemia, insulin resistance, hypertension, tachycardia, and dyslipidemia on day 77. Daily administration of plant extract for 28 days significantly improved (p<0.05-p<0.001) hemodynamic, serum biochemical, and tissue parameters. Metformin was used as a positive control. Chemical analysis of the plant extract revealed the presence of five major classes of secondary metabolites, including alkaloids, terpenoids, flavonoids, saponins, and tannins. A. thomsonii could therefore be used to improve type 2 diabetes and its cardiovascular complications.
No takes yet. Share an insight, caveat, or question.
Kevin-Armel et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: